Healthcare provider profile · identity verified

Stephen Matthew Lago, DO

Internal Medicine · LEBANON, PA · NPI 1427010701

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	802	202
Lisinopril	Lisinopril	697	171
Rosuvastatin Calcium	Rosuvastatin Calcium	664	155
Amlodipine Besylate	Amlodipine Besylate	632	148
Pantoprazole Sodium	Pantoprazole Sodium	438	121
Levothyroxine Sodium	Levothyroxine Sodium	398	101
Metformin Hcl	Metformin Hcl	388	99
Omeprazole	Omeprazole	329	83
Metoprolol Succinate	Metoprolol Succinate	304	70
Hydrochlorothiazide	Hydrochlorothiazide	296	81
Glimepiride	Glimepiride	271	70
Losartan Potassium	Losartan Potassium	262	63
Sertraline Hcl	Sertraline Hcl	228	56
Gabapentin	Gabapentin	216	64
Simvastatin	Simvastatin	215	50
Synthroid	Levothyroxine Sodium	215	45
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	199	47
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	157	38
Eliquis	Apixaban	151	35
Furosemide	Furosemide	139	43
Trazodone Hcl	Trazodone Hcl	135	34
Metoprolol Tartrate	Metoprolol Tartrate	129	33
Atenolol	Atenolol	126	29
Ozempic	Semaglutide	125	28
Tamsulosin Hcl	Tamsulosin Hcl	121	36
Alendronate Sodium	Alendronate Sodium	110	32
Albuterol Sulfate Hfa	Albuterol Sulfate	105	43
Escitalopram Oxalate	Escitalopram Oxalate	104	28
Clopidogrel	Clopidogrel Bisulfate	98	25
Allopurinol	Allopurinol	95	29
Olmesartan Medoxomil	Olmesartan Medoxomil	95	24
Pioglitazone Hcl	Pioglitazone Hcl	89	24
Citalopram Hbr	Citalopram Hydrobromide	85	22
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	84	15
Celecoxib	Celecoxib	83	21
Famotidine	Famotidine	83	20
Tramadol Hcl	Tramadol Hcl	81	21
Mirtazapine	Mirtazapine	78	18
Jardiance	Empagliflozin	73	12
Potassium Chloride	Potassium Chloride	73	19
Prednisone	Prednisone	73	46
Buspirone Hcl	Buspirone Hcl	72	26
Venlafaxine Hcl Er	Venlafaxine Hcl	72	16
Fluticasone Propionate	Fluticasone Propionate	66	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	63	13
Duloxetine Hcl	Duloxetine Hcl	57	13
Januvia	Sitagliptin Phosphate	57	14
Cephalexin	Cephalexin	54	47
Breo Ellipta	Fluticasone/Vilanterol	53	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	12
Meloxicam	Meloxicam	45	suppressed
Bupropion Xl	Bupropion Hcl	44	13
Paroxetine Hcl	Paroxetine Hcl	44	12
Ropinirole Hcl	Ropinirole Hcl	44	13
Glipizide	Glipizide	40	suppressed
Ramipril	Ramipril	40	suppressed
Carvedilol	Carvedilol	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	39	11
Propranolol Hcl Er	Propranolol Hcl	39	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Cefuroxime	Cefuroxime Axetil	35	32
Montelukast Sodium	Montelukast Sodium	33	13
Topiramate	Topiramate	32	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	31	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Glipizide Er	Glipizide	27	suppressed
Meclizine Hcl	Meclizine Hcl	27	15
Diclofenac Sodium	Diclofenac Sodium	26	11
Metformin Hcl Er	Metformin Hcl	26	suppressed
Nystatin	Nystatin	26	21
Valsartan	Valsartan	26	suppressed
Methylprednisolone	Methylprednisolone	25	23
Triamcinolone Acetonide	Triamcinolone Acetonide	24	14
Baclofen	Baclofen	22	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Terazosin Hcl	Terazosin Hcl	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	19	15
Lorazepam	Lorazepam	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	14
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Finasteride	Finasteride	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	15	suppressed
Ondansetron Odt	Ondansetron	15	12
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Dutasteride	Dutasteride	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Azithromycin	Azithromycin	11	11
Colchicine	Colchicine	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Trintellix	Vortioxetine Hydrobromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error